1. Home
  2. NKGN vs GRF Comparison

NKGN vs GRF Comparison

Compare NKGN & GRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKGN
  • GRF
  • Stock Information
  • Founded
  • NKGN 2017
  • GRF 1989
  • Country
  • NKGN United States
  • GRF United States
  • Employees
  • NKGN N/A
  • GRF N/A
  • Industry
  • NKGN Biotechnology: Biological Products (No Diagnostic Substances)
  • GRF Finance/Investors Services
  • Sector
  • NKGN Health Care
  • GRF Finance
  • Exchange
  • NKGN Nasdaq
  • GRF Nasdaq
  • Market Cap
  • NKGN 24.1M
  • GRF 36.7M
  • IPO Year
  • NKGN N/A
  • GRF N/A
  • Fundamental
  • Price
  • NKGN $1.11
  • GRF $9.41
  • Analyst Decision
  • NKGN
  • GRF
  • Analyst Count
  • NKGN 0
  • GRF 0
  • Target Price
  • NKGN N/A
  • GRF N/A
  • AVG Volume (30 Days)
  • NKGN 1.9M
  • GRF 3.0K
  • Earning Date
  • NKGN 08-16-2024
  • GRF 01-01-0001
  • Dividend Yield
  • NKGN N/A
  • GRF 3.70%
  • EPS Growth
  • NKGN N/A
  • GRF N/A
  • EPS
  • NKGN N/A
  • GRF 1.16
  • Revenue
  • NKGN N/A
  • GRF N/A
  • Revenue This Year
  • NKGN N/A
  • GRF N/A
  • Revenue Next Year
  • NKGN N/A
  • GRF N/A
  • P/E Ratio
  • NKGN N/A
  • GRF $8.15
  • Revenue Growth
  • NKGN N/A
  • GRF N/A
  • 52 Week Low
  • NKGN $0.78
  • GRF $7.93
  • 52 Week High
  • NKGN $6.70
  • GRF $10.19
  • Technical
  • Relative Strength Index (RSI)
  • NKGN 45.52
  • GRF 53.90
  • Support Level
  • NKGN $0.87
  • GRF $9.26
  • Resistance Level
  • NKGN $1.37
  • GRF $9.53
  • Average True Range (ATR)
  • NKGN 0.12
  • GRF 0.10
  • MACD
  • NKGN -0.02
  • GRF 0.01
  • Stochastic Oscillator
  • NKGN 47.70
  • GRF 74.07

About NKGN NKGen Biotech Inc.

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.

About GRF Eagle Capital Growth Fund Inc.

Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments.

Share on Social Networks: